

Don't Stay at the Heartbreak Hotel: Avoiding Catastrophic Cardiac Outcomes in Pregnant and Postpartum Women

March 1st, 2022 2-3p

Maternal Updates



Next Maternal Webinar April 5th

- Topic: GaPQC Transition to REDCap for Data Reporting & Severe Hypertension Time to Treatment (Augusta University Medical Center)

Maternal Data Reporting

- Q1 2022 (Jan-March) due by April 31st
 - NEW Data Reporting via REDCap (new process review on April 5th webinar)
- Q4 2021 Hospital Reports uploaded to Teams

Save-the-Date: GaPQC Annual Meeting October 13th and 14th



ALLIANCE FOR INNOVATION ON MATERNAL HEALTH



AIM Bundle Components



Readiness

-Unit
-Cardiac Conditions Screen
-Multidisciplinary Care Team
-Resources



Recognition and Prevention

Screening for community support needs and resources provided



Response

-Reproductive Life Planning -Patient Education



Reporting and Systems Learning

Multidisciplinary
Case Review



Respectful Care

Inclusion of the patient as part of the multidisciplinary care team

Cardiac Initiative Timeline



August 2021

AIM CCOC Webinar & Cardiac Interest Survey October 2021

Cardio-OB International Symposium November 2021

Multidisciplinary Cardiac Workgroup

March 2022

GA Educational Kick-off Webinar

April – June 2022

Cardiac Initiative Enrollment and Onboarding May 2022

GaPQC CCOC Implementation Webinar

July 2022

Data Collection
Starts

July – Ongoing Technical

Assistance

October 2022

First Data
Submission (Q3
2022) via REDCap

Cardiac Workgroup



Maternal Fetal Medicine

Obstetrics and Gynecology

Cardiology

Midwifery

Family Medicine

Emergency Medicine

Anesthesiology

Labor and Delivery

Maternal Outreach Education



Clinician and Patient Education

Intentional Cardiac Screening

Acute Management of the Cardiac Patient in Low Resource Settings

Consultation & Referral

CCOC Engagement Opportunities





Active Improvement

- ✓ Identify project champions and demonstrate facility support
- ✓ Complete Readiness Assessment
- ✓ Quarterly data submission via REDCap
- ✓ Receive quarterly hospital reports
- ✓ Improvement Coaching Support



Learning Collaborative

- ✓ Join monthly webinars, annual meeting
- ✓ No data submission
- ✓ No hospital reports
- ✓ No Improvement Coaching Support

Active Engagement Details




At minimum:

- Attend GaPQC Learning Sessions
- Submit a Quality Improvement (QI) Report Out, showing work related to implementing Key Interventions
- Complete an Initiative Specific Survey every 6 months
- Submit at least one quarter's worth of process & structure measure data during a 12- month period
- Communicate and celebrate your team's impact within your hospital and with the collaborative

Cardiac Resources on MS Teams





Cardiac Conditions in Obstetrical Care Interest Form



CLICK HERE to Complete the Survey

Please contact Lisa Ehle <u>lisa.ehle@dph.ga.gov</u> if interested in joining the cardiac workgroup





Afshan Hameed, MD
Clinical Professor, Obstetrics & Gynecology
Clinical Professor of Cardiology
University of California, Irvine
School of Medicine

CARDIAC CONDITIONS IN PREGNANCY: HOW TO IMPROVE MATERNAL OUTCOMES?

Afshan B. Hameed, MD, FACC, FACOG Professor, Maternal Fetal Medicine & Cardiology Director Obstetrics & Quality and Safety University of California, Irvine



Disclosures

• I have no financial relationships to disclose

MATERNAL MORTALITY

AIM CCOC BUNDLE

UNIVERSAL CVD RISK ASSESSMENT

MATERNAL MORTALITY

WHAT?

 What is the leading cause of maternal mortality?


WHO?

- Who is at risk?
- Are there risk factors?

WHEN?

- When does CVD related mortality occur?
- What is the timeline?

Trends in pregnancy-related mortality in the United States: 1987-2017



Causes of pregnancy-related death in the United States: 2014-2017








Figure 1: Maternal Mortality Ratio in U.S. and California, 1999-2016










Figure 5: Pregnancy-Related Mortality Ratio by Cause, California 2008-2016




Pregnancy Related Deaths 2008 - 2016




Figure 4: Pregnancy-Related Deaths by Cause, California 2008-2016 (N=608)



CDC 2007 - 2016



CDC 2007 - 2016




Causes contributing to the excess maternal mortality risk for women 35 and over, United States, 2016–2017


Marian F. MacDorman 61*, Marie Thoma2, Eugene Declercq3, Elizabeth A. Howell4

1 Maryland Population Research Center, University of Maryland, College Park, MD, United States of America, 2 Department of Family Science, University of Maryland School of Public Health, College Park, MD, United States of America, 3 Department of Community Health Sciences, Boston University School of Public Health, Boston, MA, United States of America, 4 Department of Obstetrics and Gynecology, University of Pennsylvania, Philadelphia, PA, United States of America


Late Maternal
Mortality
Rates for
PPCMP and all
other causes




Pregnancy-Related Mortality Ratio by Race/Ethnicity, California 2008 - 2016



CAUSES OF MATERNAL MORTALITY IN THE UNITED STATES 2011-2015




Pregnancy-Related Deaths by Cause + Timing to Death, California 2008 – 2016 n=608



CA-PAMR Findings 2002-2006

Timing of Diagnosis and Death


Timing of CVD Diagnosis (n=64)




Timing of Death

30% of all CVD deaths were >42 days from birth/fetal demise vs. 7.3% of non CVD pregnancy-related deaths Driven by Cardiomyopathy deaths, with 42.9% deaths >42 days

Georgia MMRC: 2012 - 2017





- Heart failure
- Arrhythmia

DEATH



Types of Cardiovascular Disease



KNOWN CARDIOVASCULAR DISEASE

PREVIOUSLY UNKNOWN OR NEW ONSET CARDIOVASCULAR DISEASE

CA-PAMR Findings 2002-2006

Presentation of Women with CVD



Abnormal physical exam findings

- HTN <u>></u>140/90 (64%)
- HR <u>></u>120 (59%)
- Crackles, S3 or gallop rhythm (44%)
- O2 <u><</u>90% (39%)

Hameed A, Lawton E, McCain CL, et al. Pregnancy-Related Cardiovascular Deaths in California: Beyond Peripartum Cardiomyopathy. AJOG 2015

IMPROVING HEALTH CARE RESPONSE TO CARDIOVASCULAR DISEASE IN PREGNANCY AND POSTPARTUM: A CALIFORNIA QUALITY IMPROVEMENT TOOLKIT

The CVD Toolkit was developed by CMQCC at Stanford University under contract with CDPH with funding from federal Title V MCH Block grant





CMQCC Cardiovascular Disease Toolkit

ALGORITHM VALIDATED IN 64 CVD DEATHS

Detection rate 93% in symptomatic cases Identified as screen-positive or high risk for CVD

Hameed, AB, Morton, CH and A Moore. Improving Health Care Response to Cardiovascular Disease in Pregnancy and Postpartum Developed under contract #11-10006 with the California Department of Public Health, Maternal, Child and Adolescent Health Division. Published by the California Department of Public Health, 2017.

©California Department of Public Health, 2017; supported by Title V funds. Developed in partnership with California Maternal Quality Care Collaborative Cardiovascular Disease in Pregnancy and Postpartum Taskforce. Visit: www.CMQCC.org for details

CVD Assessment Algorithm for Pregnant and Postpartum Women


Red Flags


- Shortness of breath at rest
- Severe orthopnea ≥ 4 pillows
- Resting HR ≥120 bpm
- Resting systolic BP ≥160 mm Hg
- Resting RR ≥30
- Oxygen saturations ≤94% with or without personal history of CVD

PROMPT EVALUATION and/or hospitalization for acute symptoms

plus

CONSULTATIONS with MFM and Primary Care/Cardiology





Cardiac Conditions in Obstetrical Care (CCOC)

https://safehealthcareforeverywoman.org/aim/patient-safety-bundles/maternal-safety-bundles/cardiac-conditions-in-obstetrical-care/




Defining Cardiac Conditions

For the purpose of this Bundle, cardiac conditions refer to disorders of the cardiovascular system which may impact maternal health



Defining Cardiac Conditions





CCOC bundle elements: 5 Rs





Readiness- Every Unit

- Train all obstetric care providers to perform a basic Cardiac Conditions Screen.
- Establish a protocol for rapid identification of potential pregnancy-related cardiac conditions in all practice settings to which pregnant and postpartum people may present.
- Develop a patient education plan based on the pregnant and postpartum person's risk of cardiac conditions.
- Establish a multidisciplinary "Pregnancy Heart Team" or consultants appropriate to their facility's designated
- Maternal Level of Care to design coordinated clinical pathways for people experiencing cardiac conditions in pregnancy and the postpartum period.
- Establish coordination of appropriate **consultation**, **co-management and/or transfer** to appropriate level of maternal or newborn care.
- Develop trauma-informed protocols and training to address health care team member biases to enhance quality of care.
- Develop and maintain a set of referral resources and communication pathways between obstetric providers, community-based organizations, and state and public health agencies to enhance quality of care.*



Recognition & Prevention

- Obtain a focused pregnancy and cardiac history in all care settings, including emergency department, urgent care, and primary care.
- In all care environments assess and document if a patient presenting is pregnant or has been pregnant within the past year.
- Assess if escalating warning signs for an imminent cardiac event are present.
- Utilize standardized cardiac risk assessment tools to identify and stratify risk.
- Conduct a risk-appropriate work-up for cardiac conditions to establish diagnosis and implement the initial management plan.
- Screen each person for condition associated risk factors and provide linkage to community services and resources.*



Response – Every Event

- Facility-wide standard protocols with checklists and escalation policies for management of cardiac symptoms.
- Facility-wide standard protocols with checklists and escalation policies for management of people with known or suspected cardiac conditions.
- Coordinate transitions of care including the discharge from the birthing facility to home and transition from postpartum care to ongoing primary and specialty care.
- Offer reproductive life planning discussions and resources, including access to a full range of contraceptive options in accordance with safe therapeutic regimens. *
- Provide patient education focused on general life-threatening postpartum complications and early warning signs, including instructions of who to notify if they have concerns, and time and date of a scheduled postpartum visit.



Reporting Systems Learning – Every Unit

- For pregnant and postpartum people at high risk for a cardiac event, establish
 a culture of multidisciplinary planning, admission huddles and post-event
 debriefs.
- Perform multidisciplinary reviews of serious complications (e.g. ICU admissions for other than observation) to identify systems issues.
- Monitor outcomes and process data related to cardiac conditions, with disaggregation by race and ethnicity due to known disparities in rates of cardiac conditions experienced by Black and Indigenous pregnant and postpartum people.



Respectful Care- Every Unit, Every Provider, Every Team Member

- Screen for structural and social drivers of health that might impact clinical recommendations or treatment plans and provide linkage to resources that align with the pregnant or postpartum person's health literacy, cultural needs, and language proficiency.
- Engage in open, transparent, and empathetic communication with pregnant and postpartum people and their identified support network to understand diagnoses, options, and treatment plans. Include each pregnant or postpartum person and their identified support network as respected members of and contributors to the multidisciplinary care team.*





Quick Links **READINESS** Printable Bundle PDF **RECOGNITION & PREVENTION** Cardiac Conditions in Obstetrical Care Element Implementation Details PDF **RESPONSE** Cardiac Conditions in Obstetrical Care Core Data Collection Plans PDF Cardiac Conditions in Obstetrical Care REPORTING/SYSTEMS LEARNING Bundle Implementation Resources PDF Cardiac Conditions in Obstetrical Care RESPECTFUL, EQUITABLE, AND SUPPORTIVE CARE Implementation Webinar

Screen for structural and social drivers of health that might impact clinical recommendations or treatment plans
and provide linkage to resources that align with the pregnant or postpartum person's health literacy, cultural

Engage in open, transparent, and empathetic communication with pregnant and postpartum people and their
identified support network to understand diagnoses, options, and treatment plans. Include each pregnant or
postpartum person and their identified support network as respected members of and contributors to the

Every Unit/Provider/Team Member

and language proficiency.

multidisciplinary care team.*

needs.

Structure Measures



Process Measures



P1: Standardized Pregnancy Risk Assessments for People with Cardiac Conditions

Denominator: Patients with cardiac conditions diagnosed prior to birth admission

Numerator: Among the denominator, those who received a pregnancy risk classification using a standardized cardiac risk assessment tool by time of birth admission



Optional Process Measure: CVD Assessment Among Pregnant and Postpartum People

Denominator: All birth admissions, whether from sample of entire population

Numerator: Among the denominator, those with documentation of a cardiovascular diseases assessment using a standardized tool



Rationale


- Currently, there is <u>one</u> CVD assessment algorithm developed for pregnant and postpartum people – the CMQCC CVD Assessment Algorithm for Pregnant and Postpartum Women.
 - Only validated using pregnancy-related deaths; needs additional validation on patients in large-scale studies.
 - Despite limitations, recognized as an emerging best practice and an important tool for assessing symptoms and risk in a standardized way.



MATERNAL MORTALITY

AIM CCOC BUNDLE

UNIVERSAL CVD RISK ASSESSMENT



California Cardiovascular Screening Tool: Findings from Initial Implementation

Elizabeth A. Blumenthal, MD, MBA¹ B. Adam Crosland, MD¹ Dana Senderoff, MD¹ Kathryn Santurino, MD² Nisha Garg, MD¹ Megan Bernstein, MD¹ Diana Wolfe, MD² Afshan Hameed, MD¹

Am J Perinatol Rep 2020;10:e362-e368.

Address for correspondence Elizabeth A. Blumenthal, MD, MBA, Department Obstetrics and Gynecology, University of California, Irvine, 101 The City Drive South, Orange, CA 92868 (e-mail: eblument@gmail.com).

¹ Department Obstetrics and Gynecology, University of California, Irvine, Orange, California

²Department Obstetrics and Gynecology, Albert Einstein School of Medicine Montefiore, The Bronx, New York

California Cardiovascular Screening Tool: Findings from Initial Implementation

Elizabeth A. Blumenthal, MD, MBA¹ B. Adam Crosland, MD¹ Dana Senderoff, MD¹ Kathryn Santurino, MD² Nisha Garg, MD¹ Megan Bernstein, MD¹ Diana Wolfe, MD² Afshan Hameed, MD¹

N=846 women screened

Screen Positive 8% (5% California, 19% New York)

NO SHOW to MFM Cardiology (70% in New York, 27% in California)

CVD Diagnosis Confirmed in 30% of Referred Cases




Fig. 2 Case selection. ASD, atrial septal defect; BP, blood pressure; CVD, cardiovascular disease; HOCM, hypertrophic obstructive cardiomyopathy; NY, New York; PFO, patent foramen ovale; SVT, supraventricular tachycardia; TIA, transient ischemic attack; UC, University of California; VSD, ventricular septal defect.



DEVELOPING CARDIOVASCULAR SCREENING MEASURES FOR PREGNANT AND POSTPARTUM WOMEN

Gordon and Betty MOORE Foundation Grant

Principal Investigator: Afshan Hameed, MD, FACOG, FACC

UCI Co-Investigators: Heike Thiel de Bocanegra, PhD, MPH

UCSD Co-Investigator: Maryam Tarsa, MD, MAS

UTenn Co-Investigator: Cornelia Graves, MD



DEVELOPING CARDIOVASULAR SCREENING MEASURES FOR PREGNANT & POSTPARTUM WOMEN

Improving Diagnostic Excellence: Gordon and Betty Moore Foundation

1. CVD Risk Assessment = All pregnant + postpartum women screened for CVD using algorithm

All pregnant + postpartum women seen at facility without prior history of known cardiac disease

2. CVD Risk Follow-up = Women who received follow up for CVD risk

Women who received follow up for CVD risk

Women who screened positive for CVD risk

Approach









Integrate CVD algorithm into the EMR

Clinicians receive immediate score **SCREEN POSITIVE**

- Follow up imaging
- Follow up laboratory test
- Follow up consultations

Follow up monitored through EMR

Upload data to UCI REDCap

- Elicit feedback
- Review measures with TEP




CVD SCREENING STEP BY STEP






ADDITIONAL OB INFO >>> CVD RISK



2 a.

CALCULATING RISK






CALCULATED RISK = NOT AT RISK




2 b.

POSSIBLE RISK FOR CVD – ADDITIONAL ORDERS



(2 c.

SCREEN + "AT RISK FOR CVD" O'Flannery, Myra Chart Rev... Results Leg... Ro... Plan ₩r... Add'l ... MyCh... 6/19/2020 visit with Major, Carol A, MD for Office Visit Prenatal Information Genetic Screening Dating CVD Risk Episodes **Preg Checklist** Results Console Referring Provider Prenatal Care Source **OB Providers UA Automated** Overview & Plan Vitals and Notes Prenatal Physical OB/Gyn Status **Procedure Notes** History Juggestive of Heurt Lutture kesung mk >=110 Yes AUE HUT Yes bpm Shortness of breath Yes No African American Yes No Systolic BP >= 140 Yes No Short of breath lying flat No Yes mmHG Pre-pregnancy obesity (BMI >=35) Respiratory Rate Yes No Rapid heart rate Yes No Pre-existing diabetes No Yes >=24 Asthma unresponsive to Yes No Oxygen Sat <=96% Yes No Hypertension therapy Cancer Diagnosis or History Yes No Suggestive of Arrhythmia Yes No Palpitations History of chemotherapy or chest Yes **Physical Exam** radiation Fainting or loss of Yes No Heart: Loud murmur Yes Substance Use consciousness Suggestive of Coronary Artery Lungs: Basilar Yes No No Nicotine use: Yes crackles Yes No Chest pain Alcohol use: No Mark All Symptoms Negative Use of risky drugs: Cocaine, Yes No Depressants (Alcohol, Barbituates, Benzodiazepines), MDMA, Ecstasy, Methamphetamines, or Opiates Substance use poses risk: Yes No Calculated Risk Possible Risk for Cardiovascular Disease Not at risk At Risk for Cardiovascular Disease



ADDITIONAL REFERRALS & ORDERS ≥2 : My Incomplete Notes ≥0 - = ■ Hyperspace - UCI MAN OB/GYN - POC - ATTENDING (UCI) OBSTETRICS eb Links 🔸 D DynaMed Plus 🚺 UpToDate 🗸 Sign My Visits 🛗 Schedule 🔤 In Basket 🏋 Remind Me 📙 Chart 💁 Encounter 📋 Doc/Orders 👢 Telephone Call 🚷 MyChart Personalizet 🔹 💙 🚱 🔑 🔓 Print 🗸 🚨 Secure 🕒 Log Out ATTENDING (UCI) OBSTETRICS Stork O'Flannery, Myra Chart Re...
Results
Leg...
Ro...
MyCh... SmartSet Progress ... OB Ch... Meani... 6/19/2020 visit with Major, Carol A, MD for Office Visit ⊕ ? Z X D D D - 15 rlannery, Myra ▼ Other Orders to Consider Current as of: Friday June 19, 2020 6:04 AM. Click to Female, 37 year old, 12/12/1982 **▼** Referrals MRN: 7008122 Consult/Referral to Maternal Fetal Medicine(high-risk/pre-pregnancy) Needs Interpreter: None OB/GYN (click to open Add'l OB Tools) * ode: Not on file (no ACP docs) Consult/Referral to Cardiology Clinic OB Delivery Location: None Consult/Referral to Internal Medicine Prenatal Care Documentation Required ? O Search ▼ Echo (+ CXR if Heart Failure or valve disease suspected) Complete 2D ECHO with Image Enhancement Agent if Necessary Cardiovascular Risk Screen Follow-up 19 OFFICE VISIT complete. Click Follow-up to X-Ray Chest Single View or Routine Prenatal Visit place recommended orders. * HR Resp BP ▼ Additional Orders 92 18 138/78 Holter Monitor (24-48 HR) Wt Myra O'Flannery Thyroid Cascade 95% 5'3" 90.7 kg CBC w/ Diff 6/19/2020 5:52 AM Office Visit MRN: 7008122 Comprehensive Metabolic Panel Description: 37 year old female Provider: Carol A Major, MD Arterial Blood Gas HIS PREGNANCY Department: Uci Man Ob/Gyn x: G2P1000 Drug Screen, Serum CSN: 33000126678 A: 13w0d (12/25/2020) lood Type: None ▼ Additional Orders **Recent Ultrasounds** O Search P No visits No resulted procedures found. You can search for an order by typing in the header of this section. △ No results OCIAL DETERMINANTS (i) Print Group [3331445969] is ome not on file deprecated. It should not be used when Associate & Edit Multiple & Providers × Remove Next creating new reports. If you are actively UC Combo Cervical Cancer... updating this report it may be beneficial to 144 Restore ✓ Close 1 Previous Next Tetanus (1 - Tdap) replace this print group with one of its B/GYN PROBLEMS (0) Scroll Back to Top Other problems (1) + ADD ORDER E PRINT AVS A ✓ SIGN VISIT + ADD DX (0)

ly Pat List Reminders: None +

SELECT LOCATION AND SIGN

My Pat List Reminders: None +

2 : My Incomplete Notes

20 - □

1 Hyperspace - UCI MAN OB/GYN - POC - ATTENDING (UCI) OBSTETRICS Web Links - D Dynamed Plus 🕕 UpToDate 🗸 Sign My Visits 🛗 Schedule 🔤 in Basket 🤻 Remind Me 📙 Chart 🤚 Encounter 📋 Doc/Orders 👢 Telephone Call 🚷 MyChart Personalizet -💙 🚱 🔑 🔓 Print 🗸 🚨 Secure 🕒 Log Out O'Flannery, Myra ATTENDING (UCI) OBSTETRICS Stork Keg... 🐠 Ro... MyCh... 🔛 Plan 😭 Wr... Chart Re... SmartSet . This Visit 💌 Progress ... OB Ch... Meani... 6/19/2020 visit with Major, Carol A, MD for Office Visit ⊕ ② Z X - - C More -D D D & - 1 Flannery, Myra Current as of: Friday June 19, 2020 6:04 AM. Click to e, 37 year old, 12/12/1982 ✓ Accept X Cancel MRN: 7008122 STAT Priority: Routine Routine Needs Interpreter: None OB/GYN (click to open Add'l OB Tools) * Code: Not on file (no ACP docs) Class: Normal Normal **OB Delivery Location: None** Referral: To dept: 8 PA 9 Prenatal Care Documentation Required ? O Search Geog areas: Default Areas IRVINE/RIVERSIDE Cardiovascular Risk Screen Follow-up ECG Indication: 6/19 OFFICE VISIT Other (Add Indication P Arrhythmia 427.9 (149.9) Atrial Fib 427.31 (148.0) complete. Click Follow-up to for Routine Prenatal Visit place recommended orders. 7 CAD 414.01 (I25.10) Chest Pain 786.50 (R07.9) HR Resp BP 92 18 138/78 Pre-Op Cardiovascular Exam V72.81 (Z01.810) Myra O'Flannery SOB 786.05 (R06.02) Tachycardia 785.0 (R00.0) 95% 5'3" 90.7 kg Clinical history 6/19/2020 5:52 AM Office Visit Suspect maternal Cardiac Disease in Pregnancy MRN: 7008122 ECG with Description: 37 year old female No Provider: Carol A Major, MD Interpretation? THIS PREGNANCY Department: Uci Man Ob/Gyn Hx: G2P1000 Comments: + Add Comments (F6) CSN: 33000126678 GA: 13w0d (12/25/2020) Blood Type: None Sched Inst.: ♣ Add Scheduling Instructions Recent Ultrasounds Ar No visits Process Inst.: No resulted procedures found. A No results SOCIAL DETERMINANTS ✓ Accept

X Cancel (i) Print Group [3331445969] is Some not on file deprecated. It should not be used when **▼** BNP creating new reports. If you are actively UC Combo Cervical Cancer... ✓ BNP Lavender ■ updating this report it may be beneficial to Tetanus (1 - Tdap) Routine, Expires: 12/19/2020, Blood replace this print group with one of its (7) Tube: Lavender Resulting Agency - LICI MEDICAL CENTER alanamatica and a language of the Other problems (1) + ADD ORDER E PRINT AVS A + ADD DX (0)

Testing a CVD Screening toolkit in pregnancy and postpartum NIH R21

PI: Afshan B. Hameed, MD

University of California, Irvine, Medical Center Health Systems
UCI Health 1,500 births a year, 3% black
Hameed/Thiel de Bocanegra/Crosland

Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, New York MMC, 6,000 births a year, 30% black Wolfe/Bernstein



3 BENEFITS OF CVD SCREENING

IDENTIFICATION OF HIGH-RISK PATIENTS

- Further cardiac testing
- Appropriate follow up

PATIENT AND PROVIDER AWARENESS AND EDUCATION

- Healthcare provider to include CVD in the differential diagnosis
- Patient more likely to seek timely medical care

OPPORTUNITY TO MODIFY RISK FACTORS


- Prevention of CVD in future
- Improved maternal and fetal outcomes
- Healthier choices

Pregnancy

Postpartum Risk Evaluation Transition to Primary Care
Interconception care

Maternal Morbidity and Mortality: Are We Getting to the "Heart" of the Matter?

Jasmina Varagic, MD, PhD, FAHA, Patrice Desvigne-Nickens, MD, Joyonna Gamble-George, MHA, PhD, Lisa Hollier, MD, MPH, Christine Maric-Bilkan, PhD, Megan Mitchell, MPH, Victoria L. Pemberton, RNC, MS, CCRC, and Nicole Redmond, MD, PhD, MPH, FACP




JOURNAL OF WOMEN'S HEALTH Volume 30, Number 2, 2021 Mary Ann Liebert, Inc. DOI: 10.1089/jwh.2020.8852 CVD risk during Pregnancy


CVD risk after Pregnancy







- CVD deaths are preventable 25% to 68%
- A large proportion of CVD deaths are > 42 day postpartum
- Most of the women who died of CVD have underlying risk factors
- Most patients present with symptoms and/or vital sign abnormalities in the postpartum period



www.cmqcc.org



THANK YOU!

Questions?
qapqc@dph.ga.gov